Literature DB >> 29197967

Effects of nutraceuticals on anaplastic thyroid cancer cells.

Lorenzo Allegri1, Francesca Rosignolo2, Catia Mio1, Sebastiano Filetti2, Federica Baldan3, Giuseppe Damante1,4.   

Abstract

PURPOSE: The anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer with a high mortality rate. Since nutraceuticals may exert beneficial effects on tumor biology, here, effects of four of these compounds [resveratrol, genistein, curcumin and epigallocatechin-3-gallate (EGCG)] on ATC cell lines were investigated.
METHODS: Two ATC-derived cell lines were used: SW1736 and 8505C. Cell viability and in vitro aggressiveness was tested by MTT and soft agar assays. Apoptosis was investigated by Western Blot, using an anti-cleaved-PARP antibody. mRNA and miRNA levels were quantified by real-time PCR.
RESULTS: All tested nutraceuticals caused in both cell lines decrease of cell viability and increase of apoptosis. In contrast, only curcumin reduced in vitro aggressiveness in both SW1736 and 8505C cell lines, while genistein and EGCG determined a reduction of colony formation only in 8505C cells. Effects on genes related to the thyroid-differentiated phenotype were also tested: resveratrol and genistein administration determined the increment of almost all tested mRNAs in both cell lines. Instead curcumin and EGCG treatments had opposite effects in the two cell lines, causing the increment of almost all the mRNAs in 8505C cells and their reduction in SW1736. Finally, effects of nutraceuticals on levels of several miRNAs, known as important in thyroid cancer progression (hsa-miR-221, hsa-miR-222, hsa-miR-21, hsa-miR-146b, hsa-miR-204), were tested. Curcumin induced a strong and significant reduction of all miR analyzed, except for has-miR-204, in both cell lines.
CONCLUSIONS: Altogether, our results clearly indicate the anti-cancer proprieties of curcumin, suggesting the promising use of this nutraceutical in ATC treatment. Resveratrol, genistein and EGCG have heterogeneous effects on molecular features of ATC cells.

Entities:  

Keywords:  Curcumin; EGCG, ATC; Genistein; Nutraceuticals; Resveratrol

Mesh:

Substances:

Year:  2017        PMID: 29197967     DOI: 10.1007/s00432-017-2555-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  49 in total

1.  Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Authors:  F Rosignolo; V Maggisano; M Sponziello; M Celano; C R T Di Gioia; M D'Agostino; L Giacomelli; A Verrienti; M Dima; V Pecce; C Durante
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

Review 2.  Thyroid cancer.

Authors:  Maria E Cabanillas; David G McFadden; Cosimo Durante
Journal:  Lancet       Date:  2016-05-27       Impact factor: 79.321

Review 3.  Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.

Authors:  Stefania Bulotta; Marilena Celano; Giuseppe Costante; Diego Russo
Journal:  Endocrine       Date:  2015-12-21       Impact factor: 3.633

Review 4.  The role of microRNAs in thyroid carcinomas.

Authors:  Stefano Forte; Cristina La Rosa; Valeria Pecce; Francesca Rosignolo; Lorenzo Memeo
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

Review 5.  The anticancer effects of resveratrol: modulation of transcription factors.

Authors:  Nichelle C Whitlock; Seung Joon Baek
Journal:  Nutr Cancer       Date:  2012-04-06       Impact factor: 2.900

6.  Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.

Authors:  Vahid Haghpanah; Parviz Fallah; Rezvan Tavakoli; Mahmood Naderi; Hilda Samimi; Masoud Soleimani; Bagher Larijani
Journal:  Tumour Biol       Date:  2015-08-20

7.  Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.

Authors:  Xiao-Min Yu; Renata Jaskula-Sztul; Kamal Ahmed; April D Harrison; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2013-04-17       Impact factor: 6.261

Review 8.  Cell growth regulation.

Authors:  Devarajan Karunagaran; Jeena Joseph; Thankayyan R Santhosh Kumar
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07
View more
  11 in total

Review 1.  Phytochemicals in thyroid cancer: analysis of the preclinical studies.

Authors:  Stefania Bulotta; Francesca Capriglione; Marilena Celano; Valeria Pecce; Diego Russo; Valentina Maggisano
Journal:  Endocrine       Date:  2021-02-15       Impact factor: 3.633

2.  The effects of Epigallocatechin-3-gallate and Dabrafenib combination on apoptosis and the genes involved in epigenetic events in anaplastic thyroid cancer cells.

Authors:  Nihal Birden; Nur Selvi Gunel; Neslihan Pinar Ozates; Bakiye Goker Bagca; Cumhur Gunduz; Leila Sabour Takanlou; Maryam Sabour Takanlou; Cigir Biray Avci
Journal:  Med Oncol       Date:  2022-05-23       Impact factor: 3.064

Review 3.  Anti-Cancer Effects of Dietary Polyphenols via ROS-Mediated Pathway with Their Modulation of MicroRNAs.

Authors:  Yasukiyo Yoshioka; Tomokazu Ohishi; Yoriyuki Nakamura; Ryuuta Fukutomi; Noriyuki Miyoshi
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

4.  Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.

Authors:  Cinzia Antognelli; Sonia Moretti; Roberta Frosini; Efisio Puxeddu; Angelo Sidoni; Vincenzo N Talesa
Journal:  Cells       Date:  2019-06-06       Impact factor: 6.600

5.  The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells.

Authors:  Lorenzo Allegri; Federica Baldan; Sudeshna Roy; Jeffrey Aubé; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.996

Review 6.  Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals.

Authors:  Seung Wan Son; Han Yeoung Lee; Sokviseth Moeng; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

7.  Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo.

Authors:  Le Xiong; Xiao-Min Lin; Jun-Hua Nie; Hai-Shan Ye; Jia Liu
Journal:  Nanotheranostics       Date:  2021-01-01

8.  Effects of Annurca Flesh Apple Polyphenols in Human Thyroid Cancer Cell Lines.

Authors:  Francesca Maria Orlandella; Peppino Mirabelli; Anna Elisa De Stefano; Paola Lucia Chiara Iervolino; Neila Luciano; Stefania D'Angelo; Giuliana Salvatore
Journal:  Oxid Med Cell Longev       Date:  2022-02-17       Impact factor: 6.543

Review 9.  Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review).

Authors:  Yitian Li; Jing Zhang; Huihui Zhou; Zhen Du
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

Review 10.  The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review).

Authors:  Yun Liu; Hongmei Sun; Bolat Makabel; Qingbin Cui; Jiajun Li; Chaoyue Su; Charles R Ashby; Zhesheng Chen; Jianye Zhang
Journal:  Oncol Rep       Date:  2019-05-03       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.